… The role of this pathway in prostate cancer has been reviewed in the past [… inhibition of this
pathway and the current status of PI3K/Akt/mTOR inhibitors in the treatment of prostate cancer …

… alterations, but not yet in prostate cancer patients (66). Prospected … to PI3K/Akt inhibitor
therapy in prostate cancer patients. … therapy with PI3K/Akt/mTOR inhibitors in prostate cancer can …

… inhibitors of this pathway have been developed with variable success. Herein we outline the
role of the PI3K pathway in prostate cancer … to AR inhibitors in prostate cancers with PTEN …

… PI3K, with Class I PI3K being the most implicated in cancer tumorigenesis and progression.
Pan-PI3K inhibitors … -class I PI3K inhibitor that have been investigated in prostate cancer. A …

… of PI3K/AKT/mTOR signalling in a range of prostate cancer primary cultures and PDXs. By
measuring the signalling and cellular responses after treatment with small molecule inhibitors …

… In particular, we address how prostate cancer cells utilize the PI3K pathway for the …
mechanisms by which prostate cancer cells become resistant to PI3K pathway inhibitors. This review …

… These changes were p110β specific because p110α knockout did not abrogate tumor
formation or AKT phosphorylation, supporting the evaluation of p110β inhibitors in prostate cancer …

… PI3K. However, the role of PIP5K1α in oncogenic processes and the development of inhibitors
… is associated with poor prognosis in prostate cancer and correlates with an elevated level …

… to pan-PI3K inhibitors, isoform-specific PI3K inhibitors only … activity, isoform-specific PI3K
inhibitors are still promising given … In preclinical studies, p110α isoform-specific PI3K inhibitors …

… The most promising pan‐PI3K/mTOR inhibitor in prostate cancer to date is … inhibitors were
superior to pan‐PI3K inhibitors. Selected ongoing trials of AKT inhibitors in prostate cancer are …